Marker Therapeutics Inc (NASDAQ:MRKR) saw its shares advance over 9% on the Nasdaq Friday after it updated investors on its clinical pipeline.
The Houston, Texas-based immuno-oncology group gave an update on five clinical trials using its targeted T-cell (MultiTAA) therapies and TPIV200, the group's peptide cancer vaccine product candidate.
In the latter (TPIV200) the group said enrolment of patients had been completed in a Phase 2 trial evaluating the drug as a therapy in patients of ovarian cancer in their first remission after surgery and platinum-based chemotherapy.
Interim data should be available by the year-end, the firm told investors.
In the triple-negative breast cancer trial, initial data from a dose-finding study of TPIV200 as maintenance therapy following first-line treatment showed a 96% immune response rate.
Elsewhere, in the lymphoma trial, 15 heavily pre-treated patients have been treated in a phase 1/2 study, the company said.
No relapses and no cases of cytokine release syndrome have been observed, while four of the six complete responders have remained in remission for three to 42 months post-infusion.
In acute lymphoblastic leukaemia, preliminary Phase 1 data showed a complete response rate of 88% over one to 22 months, the company revealed.
In the multiple myeloma trial, interim data from a Phase 1/2 trial showed an initial 100% disease control rate, including one complete responder and two partial responders, but three patients progressed after three to seven months.
Shares in New York added 9% to $6.40.